ML20195D084: Difference between revisions

From kanterella
Jump to navigation Jump to search
(StriderTol Bot insert)
 
(StriderTol Bot change)
 
Line 17: Line 17:


=Text=
=Text=
{{#Wiki_filter:}}
{{#Wiki_filter:_ - . - .          . -                        - - -      - .
  '                                                      UNITED STATES
* RELEASED TO THE PDR
. 4/[8  '
j                    NUCLEAR REGULATORY COMMISSION.
g                                            wAsamoTon. o.c. 20sss-oooi s
ff//6/'f((                M  I dato              initals g***.*                                          November 13, 1998            .
OFFICE OF THE SECRETARY MEMORANDUM TO:                William D. Travers Ex e ti ; Di ctor for O rations FROM:                        Jo Y. H yi , ecretary
 
==SUBJECT:==
AFF REQUIREMENTS - SECY-98-263 - PROPOSED RULE:
REVISION OF 10 CFR PART 35, MEDICAL USE OF BYPRODUCT MATERIAL The Commission has approved Option 2B to allow for a 30 day extension of the public comment period and the final rule date. While the extension of the final rule date is to ensure meaningful discussion with the ACMUI can be accomplished, the staff should seek to complete as much work as possible in parallelin order to attempt to meet the original due date. In addition, when the proposed final rule is submitted to the Commission, the staff should include a discussion of the risk assessment as an option and provide the pros and cons for this option.
The Commissioners' offices have designated the following points of contact for work related to the Part 35 revision:
Chairman Jackson's office:              James Smith Commissioner Dicus's office:            Joel Lubenau Commissioner Diaz's office:            Patrick Castleman Commissioner McGaffigan's office: Janet Schlueter Commissioner Merrifield's office:      Lynne Stauss The staff should continue to follow established procedures for developing and promulgating rulemakings.
                                                                                                                          ]
o
[-        3 9811170288 981113 PDR    10CFR l                    PT9.7                PDR I"1y.                                                                                                ;
5
                                                                          $'/ W          $ //*'/
1
 
i
'Yl  ,
l cc: Chairman Jackson Commissioner Dicus
!          Commissioner Diaz Commissioner McGaffigan Commissioner Merrifield OGC CIO CFO OCA OlG OPA Office Directors, Regions, ACRS, ACNW, ASLBP (via E-Mail)
PDR DCS                                                          1 1
I I
i}}

Latest revision as of 20:19, 16 December 2020

Staff Requirements Memo Re SECY-98-263 on Rev of Proposed Rule 10CFR35, Medical Use of Byproduct Matl. Commission Approved Option 2B to Allow for 30 Day Extension of Public Comment Period & Final Rule Date
ML20195D084
Person / Time
Issue date: 11/13/1998
From: Hoyle J
NRC OFFICE OF THE SECRETARY (SECY)
To: Travers W
NRC OFFICE OF THE EXECUTIVE DIRECTOR FOR OPERATIONS (EDO)
References
REF-10CFR9.7 SECY-98-263-C, NUDOCS 9811170288
Download: ML20195D084 (2)


Text

_ - . - . . - - - - - .

' UNITED STATES

  • RELEASED TO THE PDR

. 4/[8 '

j NUCLEAR REGULATORY COMMISSION.

g wAsamoTon. o.c. 20sss-oooi s

ff//6/'f(( M I dato initals g***.* November 13, 1998 .

OFFICE OF THE SECRETARY MEMORANDUM TO: William D. Travers Ex e ti ; Di ctor for O rations FROM: Jo Y. H yi , ecretary

SUBJECT:

AFF REQUIREMENTS - SECY-98-263 - PROPOSED RULE:

REVISION OF 10 CFR PART 35, MEDICAL USE OF BYPRODUCT MATERIAL The Commission has approved Option 2B to allow for a 30 day extension of the public comment period and the final rule date. While the extension of the final rule date is to ensure meaningful discussion with the ACMUI can be accomplished, the staff should seek to complete as much work as possible in parallelin order to attempt to meet the original due date. In addition, when the proposed final rule is submitted to the Commission, the staff should include a discussion of the risk assessment as an option and provide the pros and cons for this option.

The Commissioners' offices have designated the following points of contact for work related to the Part 35 revision:

Chairman Jackson's office: James Smith Commissioner Dicus's office: Joel Lubenau Commissioner Diaz's office: Patrick Castleman Commissioner McGaffigan's office: Janet Schlueter Commissioner Merrifield's office: Lynne Stauss The staff should continue to follow established procedures for developing and promulgating rulemakings.

]

o

[- 3 9811170288 981113 PDR 10CFR l PT9.7 PDR I"1y.  ;

5

$'/ W $ //*'/

1

i

'Yl ,

l cc: Chairman Jackson Commissioner Dicus

! Commissioner Diaz Commissioner McGaffigan Commissioner Merrifield OGC CIO CFO OCA OlG OPA Office Directors, Regions, ACRS, ACNW, ASLBP (via E-Mail)

PDR DCS 1 1

I I

i